Abstract
OBJECTIVE. The purpose of this article is to summarize advances in PET fluorescence resolution, agent design, and preclinical imaging that make a growing case for clinical PET fluorescence imaging. CONCLUSION. Existing SPECT, PET, fluorescence, and MRI contrast imaging techniques are already deeply integrated into the management of cancer, from initial diagnosis to the observation and management of metastases. Combined positron-emitting fluorescent contrast agents can convey new or substantial benefits that improve on these proven clinical contrast agents.
| Original language | English |
|---|---|
| Pages (from-to) | 266-273 |
| Number of pages | 8 |
| Journal | American Journal of Roentgenology |
| Volume | 207 |
| Issue number | 2 |
| DOIs | |
| State | Published - Aug 2016 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer
- Contrast medium
- Fluorescence
- Multimodality imaging
- PET
Fingerprint
Dive into the research topics of 'Dual PET and near-infrared fluorescence imaging probes as tools for imaging in oncology'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver